Industry Analysts Just Made A Captivating Upgrade To Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
The analysts have sharply increased their revenue numbers, with a view that Arcutis Biotherapeutics will make substantially more sales than they'd previously expected. Following the upgrade, the most recent consensus for Arcutis Biotherapeutics from its six analysts is for revenues of US$117m in 2024 which, if met, would be a sizeable 97% increase on its sales over the past 12 months. Losses are forecast to narrow 3.2% to US$2.21 per share. However, before this estimates update, the consensus had been expecting revenues of US$106m and US$2.35 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven. Check out our latest analysis for Arcutis Biotherapeutics These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Arcutis Biotherapeutics: Betting Big On Zoryve [Seeking Alpha]Seeking Alpha
- Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 [Yahoo! Finance]Yahoo! Finance
- Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024GlobeNewswire
- Pigmentation Disorder Treatment Market Aims for Remarkable Growth, Targeting USD 11.40 Billion by 2032 at 5% CAGR [Yahoo! Finance]Yahoo! Finance
ARQT
Earnings
- 2/27/24 - Miss
ARQT
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- ARQT's page on the SEC website